L.NewhouseS.SordilloP.GrecoK.KarapetisC
Disclosures: Phuc Le: Nothing to Disclose, Anh Phan: Nothing to Disclose, Eda Kaya: Nothing to Disclose, Yusuf Yilmaz: Nothing to Disclose, Naim Alkhouri: Madrigal: Grant/Research Support, Madrigal: Speaking and Teaching, Novo Nordisk: Consulting, Novo Nordisk: Grant/Research Support, Gilead: Grant/Research Support, Corcept: Grant/Research Support, Boehringer Ingelheim: Grant/Research Support, Echosens: Speaking and Teaching, Perspectum: Consultant, Cima: Consultant, Fibronostics: Consultant, 89Bio: Grant/Research Support, Inventiva: Grant/Research Support, Merck: Grant/Research Support, Pfizer: Grant/Research Support, Ipsen: Speaking and Teaching, Intercept: Speaking and Teaching, Madrigal: Consulting, Research Funding, Novo Nordisk: Consulting, Research Funding, Inventiva: Research Funding, Boehringer Ingelheim: Consulting, Research Funding, Corcept: Research Funding, Ipsen: Consulting, Research Funding, Gliead: Consulting, Research Funding, Speaking, Perspectum: Consulting, Research Funding, Cima: Advisor, 89Bio: Consulting, Research Funding, Akero: Grant/Research Support 1192 PATIENTS WITH ADVANCED MASLD AND DECOMPENSATION HAVE DISTINCT DIETARY HABITS Ben Byriel 1 Francis Pike 1 Harleen Kaur 1 Rebecca Gerstorff 1 Eduardo Vilar-Gomez 2 Samer Gawrieh 1 Raj Vuppalanchi 1 Naga Chalasani 3 Niharika Samala 1 , 1 Indiana University, 2 Richard L
(27) noted higher rates of peeling (up to 70%) and burning (up to 45%), along with erythema and PIH, although these were mild, transient, and did not lead to dropouts
GLP-1, glucagon-likepeptide-1
